 |
|
| Blog results | Results 1 - 10 of about 340 for lapatinib and capecitabine. (0.20 seconds) |
| Sorted by relevance Sort by date |
| 14 Dec 2009 by Syn-chemist On March 13, 2007, FDA approved lapatinib in combination therapy for breast cancer patients already using capecitabine. Recently, researchers from Duke University Medical Center. Dr. Kimberly Blackwell have found more interesting ... Med-Chemist - http://synchemist.blogspot.com/ |
| 1 Dec 2009 by godsmorally The cost-effectiveness of lapatinib plus capecitabine was supported by a resemblance to trastuzumab-containing regimens, and capecitabine singular, representing the established treatment regimens in NHS clinical technique. ... godsmorally - http://godsmorally.chrisbrownconnection.com/ |
| 14 Dec 2009 To qualify for enrollment, patients must have undergone prior treatment with regimens that included an anthracycline, a taxane, trastuzumab (Herceptin®), lapatinib (Tykerb®) and capecitabine (Xeloda®).1. Among the data reported were: ... Drugs.com - Clinical Trials - http://www.drugs.com/clinical_trials.html [ More results from Drugs.com - Clinical Trials ] |
| 14 Dec 2009 by CancerCompass ... advanced breast cancer whose disease had progressed after receiving at least two prior HER2-targeted treatments (trastuzumab and lapatinib) in the metastatic setting, as well as an anthracycline, a taxane, and capecitabine. ... Breast Cancer News Articles Provided by... - http://www.cancercompass.com/ |
| 20 Oct 2009 by Dr. NICK BACKGROUND: The Lapatinib Expanded Access Program (LEAP) was designed to provide access to lapatinib plus capecitabine for HER2-positive metastatic breast cancer patients who previously received an anthracycline, a taxane, ... CANCER AND IMPORTANT MEDICAL NEWS - http://cancerology.blogspot.com/ |
| 21 Oct 2009 Lapatinib (in combination with capecitabine), within its licensed indication, is not recommended for the routine treatment of women with previously treated advanced or metastatic breast cancer whose tumours over-express HER2, ... NeLM - News - http://www.nelm.nhs.uk/en/NeLM-Area/News/ [ More results from NeLM - News ] |
| 25 Aug 2009 status: recruiting, condition summary: breast cancer; metastatic cancer. Clinical Trials Updates During the Last 7 Days - http://clinicaltrialsfeeds.org/clinical-trials/r... [ More results from Clinical Trials Updates During the Last 7 Days ] |
| 12 Aug 2009 by Christopher M. Hughes, MD Using the investigator assessment of the clinical benefit response rate a greater proportion of subjects in the lapatinib+capecitabine group (37%) than in the capecitabine group (21%) achieved clinical benefit (two-sided p-value: 0.001) ... The Health Care Reform Debate Blog - cmhmd - http://cmhmd.blogspot.com/ |
| 23 Jun 2009 by admin In its final appraisal determination NICE acknowledges that lapatinib is a clinically effective option, noting that lapatinib plus capecitabine demonstrated improved time to progression (TTP) and progression free survival (PFS) ... Nordwave Great Britain - http://nordwave.net/Great_Britain/ |
| 6 Aug 2009 by plasmanegative lin, nu, lapatinib and capecitabine for the treatment of brain metastases in patients with her2+ breast cancer — an updated analysis from egf105084., presented at the 2007 san antonio breast cancer symposium, san antonio, tx, ... Plasma negative - http://hardwarereactor.de/plasmanegative/ |
Stay up to date on these results:
| Google Home - About Google Blog Search Beta - Information for Blog Authors |
